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Abstract
Background: Statins (3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors) consumption provides
beneficial effects on cardiovascular systems. However, effects of statins on vascular KATP channel gatings are unknown.
Methods: Pig left anterior descending coronary artery and human left internal mammary artery were isolated and
endothelium-denuded for tension measurements and Western immunoblots. Enzymatically-dissociated/cultured arterial
myocytes were used for patch-clamp electrophysiological studies and for [Ca2+]i, [ATP]i and [glucose]o uptake
measurements.
Results: The cromakalim (10 nM to 10 mM)- and pinacidil (10 nM to 10 mM)-induced concentration-dependent relaxation of
porcine coronary artery was inhibited by simvastatin (3 and 10 mM). Simvastatin (1, 3 and 10 mM) suppressed (in okadaic
acid (10 nM)-sensitive manner) cromakalim (10 mM)- and pinacidil (10 mM)-mediated opening of whole-cell KATP channels of
arterial myocytes. Simvastatin (10 mM) and AICAR (1 mM) elicited a time-dependent, compound C (1 mM)-sensitive [3H]-2-
deoxy-glucose uptake and an increase in [ATP]i levels. A time (2–30 min)- and concentration (0.1–10 mM)-dependent
increase by simvastatin of p-AMPKa-Thr172 and p-PP2A-Tyr307 expression was observed. The enhanced p-AMPKa-Thr172
expression was inhibited by compound C, ryanodine (100 mM) and KN93 (10 mM). Simvastatin-induced p-PP2A-Tyr307
expression was suppressed by okadaic acid, compound C, ryanodine, KN93, phloridzin (1 mM), ouabain (10 mM), and in
[glucose]o-free or [Na
+]o-free conditions.
Conclusions: Simvastatin causes ryanodine-sensitive Ca2+ release which is important for AMPKa-Thr172 phosphorylation via
Ca2+/CaMK II. AMPKa-Thr172 phosphorylation causes [glucose]o uptake (and an [ATP]i increase), closure of KATP channels, and
phosphorylation of AMPKa-Thr172 and PP2A-Tyr307 resulted. Phosphorylation of PP2A-Tyr307 occurs at a site downstream of
AMPKa-Thr172 phosphorylation.
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Introduction
3-Hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reduc-
tase is a 97-kDa glycoprotein embedded in the endoplasmic
reticulum [1] which is involved in the endogenous cholesterol
biosynthesis in mammalian liver and intestine [2]. Pervious study
of our group [3] has clearly illustrated the biochemical existence of
extra-hepatic HMG-CoA reductase in human and porcine
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cardiovascular tissues, suggesting a physiological role of this
enzyme in the cardiovascular system. HMG-CoA reductase
inhibitors, commonly known as statins, have been shown to be
an effective treatment of hypercholesterolemia and cardiovascular
diseases via its cholesterol-lowering property and cholesterol-
independent effects (pleiotropic effects) [3,4,5,6,7,8].
Regulation of vascular tone relies on complex cellular mecha-
nisms as well as the opening and closing of various ion channels.
Previous studies have demonstrated that statins can modify the
activities of different ion channels in blood vessels including L-type
Ca2+ channel and BKCa channel [3,9,10,11]. In addition to Ca
2+
channels and BKCa channels, ATP-sensitive K
+ (KATP) channels
are abundant in vascular tissues and KATP channels are also
important in regulating the vascular tone [12]. In rat isolated
aorta, cerivastatin-induced a glibenclamide (a KATP channel
blocker)-sensitive aortic relaxation [13] and pravastatin reduced
myocardial infact size through opening of mitochondrial KATP
channels in rabbit [14]. However, a recent study reported that
simvastatin, but not pravastatin, inhibited pinacidil (a KATP
channel opener)-induced relaxation of pig’s isolated coronary
arteries suggesting that different statins have differential effects on
KATP channels of different cells/tissues [40].
Similar to other ion channels, the opening and closing of KATP
channels are modulated by multiple cell signaling mechanisms,
such as phosphorylation by protein kinase A (PKA) [15], protein
kinase C (PKC) [16] and cGMP-dependent protein kinase (PKG)
[17]. In addition, the intracellular ATP level is an essential
determinant of KATP channel gatings. It is well-known that AMP-
activated protein kinase (AMPK) serves as a ‘metabolic master
regulator’ which is sensitive to changes of intracellular AMP/ATP
ratio. Activation of AMPK results in suppression of intracellular
energy-consuming pathways and generation of ATP i.e. an
increase in cellular ATP level. In mouse isolated pancreatic islets,
activation of AMPK by AICAR (an AMPK activator) potentiated
insulin secretion by inhibiting KATP channel openings [18].
Moreover, phenformin (another AMPK activator), inhibited KATP
channel openings in mouse aortic smooth muscle cells [19],
highlighting the participation of AMPK activity in KATP channel
gatings in VSMC. Unfortunately, in various ex vivo studies (multi-
cellular preparations), there is no consensus on the vascular effects
mediated by AMPK activation as both contraction and relaxation
were observed [20,21,22,23,24], and the underlying reason(s) for
the discrepancy is unknown. Given the fact that statins promoted
phosphorylation of AMPK in human and bovine endothelial cells
[25], it is tempting to suggest that activation of AMPK by
simvastatin could modulate vascular KATP channel gatings and
vascular reactivity.
Therefore, in this study we hypothesize that acute simvastatin
could modulate vascular KATP channel gatings and the simvas-
tatin-mediated effects involve activation of AMPK signaling
pathway. Thus, in this study, experiments were designed to
evaluate the effects of acute simvastatin on vascular KATP channel
gatings of pig’s coronary artery, and the participation of AMPK
activation.
Materials and Methods
Animal and Human Ethics Statements
This investigation conformed to the Guide for the Care and Use
of Laboratory Animals published by the US National Institute of
Health (NIH Publication No. 85–23, revised 1996). The protocol
was approved by the Animal Ethics Committee of the Chinese
University of Hong Kong (Approval Number: 10/003/DRG).
Permission prior to the collection of fresh pig’s heart for research
purposes was obtained from Sheung Shui Slaughterhouse (Hong
Kong).
Fresh human left internal mammary arteries were the leftover
obtained from patients with cardiovascular diseases undergoing
coronary artery bypass grafting (CABG) procedures, and the use of
human tissues for research purposes was approved by the Human
Research Ethics Committee of the Chinese University of Hong
Kong (CREC Ref. No. 2006.313). Written consents were
obtained, prior to surgery, from patients voluntarily involved for
the usage of tissues solely for research purposes. Patients had read
and understood the patient information document provided, and
the aims and methods of this study had been fully explained to
them. Patients involved had given written informed consent (as
outlined in PLOS consent form) to authors of this manuscript for
publication of these data.
Isometric Tension Measurement
Fresh hearts were obtained from pigs (,35 kg) that were
slaughtered in the morning of the experiment at a local
slaughterhouse. The heart was immediately immersed in an ice-
cold physiological salt solution. Segment of the left anterior
descending (LAD) coronary artery (tertiary branch, O.D. ,500–
800 mm) was dissected within an hour after the animal was
slaughtered.
Fresh human left internal mammary arteries were bathed in an
ice-cold physiological salt solution before transported to the
laboratory from the operation theatre of the Prince of Wales
Hospital (Hong Kong) within an hour. Fat and connective tissues
were carefully removed under the dissecting stereo-microscope.
Arterial rings (porcine coronary artery and human internal
mammary artery) (endothelium was removed using a blunted
watch-maker forceps) were bathed in a 5-ml thermo-regulated
wire myograph contained physiological salt solution with the
composition (mM): NaCl 118.3, KCl 4.6, MgSO4 1.2, NaHCO3
25, KH2PO4 1.2, CaCl2 2.5, and glucose 11 (bubbled with
16%O2/5%CO2 balanced with N2, pO2=,100 mmHg). Rings
(1 mm in length) were equilibrated under resting tension of 1 g
[26,27] using two stainless steel wires (diameter ,100 mm), in the
bath solution for 90 min. Resting tension was re-adjusted, if
necessary, before commencing the experiments. The reason for
choosing these tissues in this study is because previous reports
demonstrated the existence of KATP channels in these vascular
tissues [28,29].
Enzymatic Dissociation of Myocytes
Porcine left anterior descending coronary artery myocytes and
human left internal mammary artery myocytes were dissociated
using collagenase and protease, as reported [3,13] for conventional
whole-cell patch-clamp electrophysiology experiments.
Electrophysiological Measurement of KATP Gatings
Conventional whole-cell, patch-clamp experiments were per-
formed at room temperature (, 22uC) using single-cell, voltage-
clamp techniques (Axopatch 200B amplifier and Digidata
1200 A/D interface) (Axon Instruments, USA) with recording
patch pipettes of 2–4 MV (when filled with internal pipette
solution). Whole-cell recording configurations were used so as to
maintain a ‘‘pre-determined concentration’’ of ATP (i.e. 1 mM)
inside all the cells used during the recording of KATP channels for
a fair/accurate comparison of KATP channel gatings of different
cells (pig coronary artery and human internal mammary artery) in
response to drug challenges. In addition, this mode of recording
offers the convenience of a rapid delivery of drugs (e.g. simvastatin
Na+, okadaic acid and rottlerin) into the cytosol of cells.
Simvastatin Inhibits KATP Channels
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The external bath solution contained (mM): KCl 10, potassium
gluconate 135, EGTA 5, glucose 5 and HEPES 10 (pH=7.4). The
internal pipette solution contained (mM): KCl 10, potassium
gluconate 133, EGTA 5, glucose 5, K2ATP 1, NaADP 0.5, MgCl2
1 and HEPES 10 (pH=7.4) [15]. The cell was held at 0 mV, and
pulse voltages from –100 to +40 mV with a 20-mV increment
(with pulse duration of 1 s, stimulated at 0.1 Hz) were applied.
Current records were low-pass filtered, digitized and stored on
computer hard-disk for later analysis using the Clampfit 9
softwares (Axon Instruments, USA).
Confocal Laser Scanning Microscopy
Porcine coronary artery myocytes were incubated with Fluo-4/
AM (5 mM in 0.05% DMSO) (60 min, 37uC) in HEPES buffer
(mM): NaCl 140, KCl 5, MgCl2 1, CaCl2 1, glucose 10, and
HEPES 10 (pH 7.4). After washing, myocytes were imaged using
an Eclipse CL Plus Confocal Microscope System (Nikon, Japan)
with an excitation at 488 nm and a band-pass filter at 515/
530 nm. Fluorescence changes of myocytes (at room temperature)
in response to drugs (simvastatin (10 mM) and AICAR (1 mM),
with and without ryanodine (100 mM)) were acquired at 15-s
intervals. Images were recorded and analyzed by software EZ-C1
3.5 (Nikon, Japan).
Measurement of [Glucose]o Uptake
[3H]-2-Deoxy-glucose uptake into porcine coronary artery
myocytes was determined using previously described protocols
with minor modifications [30]. All experiments were performed in
HEPES-buffered Ringer’s solution containing (mM): NaCl 135;
KCl 5; NaH2PO4 3.33; Na2HPO4 0.83; CaCl2 1.0; MgCl2 1.0 and
HEPES 5 (pH 7.4). Confluent monolayer of cultured porcine
coronary artery myocytes in 24-well plates were washed three
times in Ringer’s solution. [3H]-2-Deoxy-glucose (10 mM, 4 mCi/
ml) was added to each well and incubated for 30 min (37uC). The
plates were then washed three times rapidly with ice-cold
phosphate-buffered saline before cells were solubilized in 0.5 ml
of Triton X-100 (5% vol./vol.). To determine non-specific uptake
of [3H]-2-deoxy-glucose, cells were incubated in buffer containing
[3H]-2-deoxy-glucose in the presence of cytochalasin B (50 mM)
and phloretin (100 mM). The radioactivity was measured using a
b-scintillation counter. The protein content was determined
spectrophotometrically using the bicinchoninic acid assay (Pierce
Biochemicals, USA).
Determination of Cellular ATP Contents
ATP was extracted from cultured porcine coronary artery
myocytes (before and after drug treatments) by trichloroacetic acid
(final concentration, 0.5% vol./vol.). Trichloroacetic acid in the
sample was then neutralized and diluted to a final concentration of
0.1% by adding Tris-acetate buffer (pH 7.75). The ATP content
was analyzed using the ATP-dependent luciferin-luciferase biolu-
minescence assay (ENLITENH ATP assay system, Promega,
USA).
Western Immunoblots
Isolated porcine coronary artery and human internal mammary
artery (both were endothelium denuded) were homogenized in the
presence of protease inhibitors (Roche, USA) to obtain extracts of
proteins. Protein concentrations were determined using BCATM
protein assay kit (Pierce, USA). Samples (40 mg of protein per lane)
were loaded onto a 10% SDS-polyacrylamide electrophoresis gel.
After electrophoresis (90 V, 120 min), the separated proteins were
transferred (12 mA, 45 min) to polyvinylidene difluoride mem-
brane (Bio-Rad, USA). Non-specific sites were blocked with 5%
non-fat dry milk (Bio-Rad, USA) for 120 min, and the blots were
then incubated with individual type of antibody: anti-HMG CoA
reductase, 1:1,000 (Upstate Biotechnology, USA); anti-p-HMG
CoA reductase-Ser871, 1:1,000 (Kinasource, UK); anti-CYP450
3A4, 1:1,000 (Affinity Bioreagent, USA); anti-PP2A, 1:1,000
(Upstate Biotechnology, USA); anti-p-PP2A-Tyr307, 1:1,000 (Up-
state Biotechnology, USA); anti-AMPK, 1:1,000 (Upstate Bio-
technology, USA), anti-p-AMPKa-Thr172, 1:1,000 (Upstate Bio-
technology, USA); anti-LKB1, 1:1,000 (Upstate Biotechnology,
USA) and anti-p-LKB1-Ser428, 1:1,000 (Upstate Biotechnology,
USA) overnight at 4uC. Anti-mouse HRP conjugated IgG, 1:1,000
(Bio-Rad, USA) or anti-rabbit HRP conjugated IgG, 1:1,000 (Bio-
Rad, USA) was used to detect the binding of the corresponding
antibody. Membranes were stripped and re-blotted with anti-b-
actin antibody, 1:10,000 (Sigma-Aldrich, USA) to verify an equal
loading of protein in each lane. The protein expression was
detected with ImmueStar Reagent (Bio-Rad, USA) and quantified
using Scion Image analysis programme (Scion Image Ltd., USA).
Chemicals
Simvastatin, cromakalim, glibenclamide, AICAR, compound
C, rottlerin, ryanodine, caffeine, U46619, KB R-7953 mesylate,
H89 dihydrochloride, okadaic acid, KN93 and KN92 were
purchased from Tocris Biosciences (UK). Simvastatin Na+
(50 mmol/L) was prepared from simvastatin using NaOH (in
ethanol), as suggested by the manufacturer (Tocris Biosciences,
UK). Nifedipine, D-mannitol, pinacidil, ouabain, phloridzin, 5-(N-
ethyl-N-isopropyl) amiloride (EIPA), N-methyl-D-glucamine chlo-
ride and ketoconazole were obtained from Sigma-Aldrich (USA).
Statistical Analysis
All data were obtained from at least 6 independent experiments.
Statistical analysis was performed using Student’s t test or
ANOVA (one-way or two-way), where appropriate. A P value of
,0.05 was considered significant. Data are expressed as mean 6
S.EM.
Results
Biochemical Existence of HMG-CoA Reductase and the
Effects of Simvastatin and Simvastatin Na+ on HMG-CoA
Reductase Expression
The biochemical existence of HMG CoA reductase was
determined in both human isolated left internal mammary artery
and porcine isolated coronary artery. Porcine liver served as the
positive control. Western blot results confirmed the biochemical
existence of HMG-CoA reductase in both human and porcine
vascular preparations. Beta actin was used as a loading control
(Figure 1A).
We then investigated the effects of simvastatin and simvastatin
Na+ in inhibiting HMG CoA reductase activity (i.e. phosphory-
lation of HMG CoA reductase) [29]. Neither simvastatin nor
simvastatin Na+ (10 mM, incubation # 30 min) altered the protein
expression of p-HMG-CoA reductase-Ser871 and HMG-CoA
reductase in porcine isolated coronary artery (Figure 1B).
Effects of Simvastatin on KATP Channel Opener-induced
Relaxation
To evaluate the involvement of KATP channels, effects of
simvastatin on KATP channel opener-mediated vascular relaxation
were examined. Cromakalim and pinacidil (both are KATP
channel openers) (10 nM to 10 mM) caused a glibenclamide (1
Simvastatin Inhibits KATP Channels
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and 3 mM)-sensitive relaxation of U46619 (10 nM) pre-constricted
coronary artery (endothelium-denuded) relaxation in a concen-
tration-dependent manner (data not shown). Glibenclamide alone
did not alter the basal tension and U46619-induced contraction.
Simvastatin (3 and 10 mM), but not simvastatin Na+ (1, 3 and
10 mM), significantly attenuated cromakalim- and pinacidil-
induced relaxation (Figure 2A and B). Neither simvastatin nor
simvastatin Na+ altered the basal tension of the preparation.
Okadaic acid (a potent PP2A inhibitor) was used to elucidate the
involvement of PP2A in simvastatin-suppressed cromoakalim- and
pinacidil-inudced relaxation. Okadaic acid (10 nM) eradicated
simvastatin (10 mM)-induced inhibition of cromakalim- and
pinacidil-induced relaxation (n= 6) (Figure 2C and D). Okadaic
acid (10 nM) alone did not modify cromakalim-induced relaxa-
tion.
Effects Simvastatin on KATP Openings
In order to get a better understanding on the modulation of
KATP channels gatings by simvastatin, experiments were per-
formed in single vascular myocytes. Cromakalim (10 mM)
(Figure 3A) and pinacidil (10 mM) (data not shown) significantly
enhanced the recorded outward K+ current amplitude which is
inhibited by glibenclamide (a KATP channel blocker), indicating
that the recorded K+ current is the genuine KATP current.
In human internal mammary artery myocytes, neither simvas-
tatin (1, 3 and 10 mM) nor simvastatin Na+ (1, 3 and 10 mM)
altered the basal KATP channel gatings (data not shown).
Figure 1. Biochemical existence of HMG-CoA reductase, and the effects of simvastatin and simvastatin Na+ on the protein
expression of HMG-CoA reductase and p-HMG-CoA reductase. (A) Biochemical existence of HMG-CoA reductase in porcine liver, porcine
coronary artery (endothelium-denuded) and human left internal mammary artery (endothelium-denuded). Beta actin was used as loading control. (B)
Effects of simvastatin (SIM) (10 mM) and simvastatin Na+ (SIM Na+) (10 mM) (incubation, 2 to 30 min) on the protein expression of p-HMG-CoA
reductase-Ser871 and HMG-CoA reductase of porcine coronary artery.
doi:10.1371/journal.pone.0066404.g001
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Interestingly, simvastatin caused a concentration-dependent inhi-
bition of cromakalim (10 mM)-induced KATP channel opening,
with no apparent recovery after washout (Figure 3B). However,
simvastatin Na+ (10 mM, applied either in external bath solution or
included in the pipette solution) did not alter cromakalim (10 mM)-
induced KATP opening (data not shown).
Due to the irregular/limited supply of human left internal
mammary artery for research purposes, the following experiments
were performed using porcine coronary artery myocytes. All
drugs/inhibitors were tested against both cromakalim- and
pinacidil-induced KATP opening, however only representative
figures of drug modulation of cromakalim-mediated responses
were illustrated in the Figures.
Okadaic acid (a potent PP2A inhibitor) was used to examine the
involvement of PP2A in simvastatin-mediated suppression of
cromakalim- and pinacidil-induced KATP opening. Okadaic acid
(10 nM) did not alter the basal KATP openings, and cromakalim
(10 mM)- and pinacidil (10 mM)-induced KATP openings. Howev-
er, okadaic acid (10 nM, in the pipette solution) significantly
attenuated simvastatin (10 mM)-mediated suppression of croma-
kalim (10 mM)- and pinacidil (10 mM)-induced KATP openings
(Figure 3C). In contrast, okadaic acid failed to alter glibenclamide
(3 mM)-mediated inhibition of cromakalim- and pinacidil-induced
KATP openings (Figure 3C).
The involvement of AMPK on cromakalim- and pinacidil-
induced KATP channel openings was examined. Similar to
simvastatin (10 mM), AICAR (1 mM, an AMPK activator)
attenuated cromakalim- and pinacidil-induced KATP channel
openings (Figure 3D). However, AICAR (1 mM) did not alter
the basal KATP amplitude (data not shown).
Effects of Simvastatin on AMPK and PP2A
Phosphorylation
To strengthen our hypothesis on the participation of AMPK
activation on mediating simvastatin-induced responses, we evalu-
ated AMPK activity using Western blots. Activity of AMPK is
represented by p-AMPKa-Thr172/total AMPK, as previously
demonstrated [31]. AICAR (1 mM) and simvastatin (10 mM)
caused a time-dependent (2–30 min) increase of AMPK activation
(i.e. increased p-AMPKa-Thr172 expression) (Figure 4A and B).
These responses were sensitive to Compound C (an AMPK
inhibitor) (1 mM; 30 min) (Figure 4C). Okadaic acid (10 nM,
30 min) (Figure 4D) did not alter simvastatin (10 mM)-mediated
increase of AMPK activity.
The role of PP2A activation (represented by p-PP2A-Tyr307/
total PP2A), as previously reported [32], in response to simvastatin
and AICAR challenges was evaluated using okadaic acid and
Compound C. Simvastatin (10 mM) and AICAR (1 mM) elicited a
time-dependent (2 to 30 min) increase in p-PP2A-Tyr307/total
PP2A (i.e. a decreased PP2A activity) (Figure 5A and B).
Simvastatin (10 mM)- and AICAR (1 mM)-induced decrease of
PP2A activity was eradicated by okadaic acid (10 nM, 30 min) and
Compound C (1 mM, 30 min) (Figure 5C and D).
Role(s) of [Ca2+]o and [Ca
2+]i in Mediating Effects of
Simvastatin on AMPK and PP2A Activities
Ca2+ ions are important in mediating various cellular signaling
cascades. The significance of [Ca2+]o and [Ca
2+]i in mediating
simvastatin-induced responses was therefore evaluated. Simvasta-
tin (10 mM) caused an increase in [Ca2+]i level and contraction of
single myocytes (data not shown). In myocytes challenged with
ryanodine (100 mM), there was a transient increase in [Ca2+]i,
(plus contraction of single myocytes) and the subsequent applica-
tion of simvastatin (10 mM) (Figure 6A and B) failed to alter
[Ca2+]i levels.
To elucidate the role of changes in [Ca2+]i in mediating
simvastatin-induced AMPK activation as shown above, effects of
ryanodine, [Ca2+]o-free solution, KB R-7953 and nifedipine were
examined. Ryanodine (100 mM, 30 min pre-treatment) abolished
simvastatin (10 mM)-, but not AICAR (1 mM)-, induced AMPK
activation (Figure 6C). Caffeine (1 mM) caused a time-dependent
(2 to 30 min) (ryanodine-sensitive) AMPK activation (Figure 6D).
Ryanodine, on its own, did not alter AMPK activation.
Ryanodine pre-treatment (100 mM) abolished simvastatin
(10 mM)-, AICAR (1 mM) and caffeine (1 mM)-induced changes
of p-PP2A-Tyr307/total PP2A (Figure 6E). Moreover, effects of
simvastatin (10 mM)- and caffeine (1 mM)-, but not AICAR
(1 mM)-, on PP2A activities were abolished by KN 93 (10 mM)
(Figure 6F), but not by KN 92 (10 mM) (data not shown). In
addition, effects of simvastatin (10 mM) and AICAR (1 mM) on
AMPK and PP2A activities were not modified by [Ca2+]o-free
solution (with EGTA, 2 mM), KB R-7953 (10 mM)- or nifedipine
(10 mM)-containing solutions (data not shown).
Effects Simvastatin and AICAR on [Glucose]o Uptake
In order to establish the role of [glucose]o, effects of simvastatin
and AICAR on [glucose]o uptake was determined. Simvastatin
(10 mM) and AICAR (1 mM) caused a significant increase in [3H]-
2-deoxy-glucose uptake into coronary artery myocytes, and the
‘‘enhanced’’ [glucose]o uptake was eradicated by Compound C
(10 mM) (Figure 7A).
The Role(s) of [Glucose]o and [Na
+]o in Mediating
Simvastatin Effects on AMPK and PP2A Activities
After the confirmation of the essential role of [glucose]o as
mentioned above, identification of the [glucose]o uptake trans-
porter involved was performed. [Glucose]o-free solution (osmotic
balanced with D-mannitol), phloridzin (1 mM, a Na+/glucose co-
transporter-1 (SGLT-1) blocker), ouabain (10 mM, a Na+/K+
ATPase inhibitor), 5-(N-ethyl-N-isopropyl) amiloride (EIPA,
10 mM) (a Na+/H+ exchanger-1 blocker) and [Na+]o-free (replaced
with N-methyl-D-glucamine) solution failed to alter simvastatin
(10 mM)- and AICAR (1 mM)-mediated increase of p-AMPKa-
Thr172 expression (data not shown). In contrast, simvastatin
(10 mM)- and AICAR (1 mM)-mediated increase of p-PP2A-
Tyr307/total PP2A (i.e. PP2A inhibition) was eradicated in
[glucose]o-free (Figure 7B) or [Na
+]o-free conditions (Figure 7C),
and with phloridzin (1 mM)- (Figure 7D) or ouabain (10 mM)-
containing solutions (Figure 7E). However, EIPA (10 mM) did not
Figure 2. Effects of simvastatin on KATP channel openers-induced vasorelaxation. (A) Effect of simvastatin (1, 3 and 10 mM) (n = 6 to 8) on
cromakalim-induced relaxation of U46619 (10 nM) pre-contracted porcine coronary artery (endothelium-denuded). (B) Effect of simvastatin (1, 3 and
10 mM) (n = 6 to 8) on pinacidil-induced relaxation of U46619 (10 nM) pre-contracted porcine coronary artery (endothelium-denuded). (C) Effect of
okadaic acid (10 nM) (n = 6 to 8) on simvastatin-inhibited cromakalim-induced relaxation of U46619 (10 nM) pre-contracted porcine coronary artery
(endothelium-denuded). (D) Effect of okadaic acid (10 nM) (n = 6 to 8) on simvastatin-inhibited pinacidil-induced relaxation of U46619 (10 nM) pre-
contracted porcine coronary artery (endothelium-denuded). *P,0.05, **P,0.01 and ***P,0.001 compared to controls.
doi:10.1371/journal.pone.0066404.g002
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modify simvastatin (10 mM)- and AICAR (1 mM)-mediated
changes of p-PP2A-Tyr307/total PP2A (data not shown).
Effects of Simvastatin on [ATP]i Levels and LKB1
Activation
To confirm the generation of [ATP]i after [glucose]o uptake
induced by simvastatin, cellular ATP level was estimated in
response to drug challenges. AICAR caused a Compound C
(10 mM)-sensitive increase in cellular ATP level of the arterial
Figure 3. Effects of simvastatin on KATP channel openings. (A) Effects of cromakalim (Crom., 10 mM) on whole-cell KATP channel openings of
single human internal mammary artery myocytes in the presence of glibenclamide (Glib., 3 mM) (n = 5 to 6). (B) Effects of cromakalim (Crom., 10 mM)
on whole-cell KATP channel openings of single human internal mammary artery myocytes with and without simvastatin (1, 3 and 10 mM). (C) Effects of
simvastatin (10 mM) and glibenclamide (Glib., 3 mM) on cromakalim (Crom., 10 mM)-induced whole-cell KATP channel openings of single porcine artery
myocytes (in the presence of okadaic acid, 10 nM). Number of cells studied is indicated in parenthesis. *P,0.05, **P,0.01 and ***P,0.001 compared
to controls. (D) Effects of cromakalim (Crom., 10 mM) on whole-cell KATP channel openings of single porcine coronary artery myocytes in the presence
of AICAR (1 mM). Number of cells studied is indicated in parenthesis. *P,0.05, **P,0.01 and ***P,0.001 compared to controls.
doi:10.1371/journal.pone.0066404.g003
Figure 4. Effects of simvastatin on AMPK activation in porcine coronary artery. (A) Effects of AICAR (1 mM) on the protein expression of p-
AMPK/total AMPK in porcine coronary artery. *P,0.05 and **P,0.01 compared to controls (i.e. time 0). (B) Effects of simvastatin (10 mM) on the
protein expression of p-AMPK/total AMPK in porcine coronary artery. *P,0.05 and **P,0.01 compared to controls (i.e. time 0). (C) Effect of
compound C (10 mM) on simvastatin- and AICAR-induced AMPK activation (p-AMPK/total AMPK) in porcine coronary artery. *P,0.05 and **P,0.01
compared to controls (i.e. time 0). (D) Effect of okadaic acid (10 nM) on simvastatin-induced AMPK activation (p-AMPK/total AMPK) in porcine
coronary artery. *P,0.05 and **P,0.01 compared to controls (i.e. time 0).
doi:10.1371/journal.pone.0066404.g004
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myocytes (Figure 8A) and a time-dependent (2 to 30 min) increase
in LKB1 activity (i.e. an increase in p-LKB1-Ser428/total LKB1
[33]) (Figure 8B). However, simvastatin increased intracellular
ATP level of the arterial myocytes with no apparent change in p-
LKB1/total LKB1 (Figure 8C).
Participation of Cytochrome P450 3A4
To elucidate the importance of cytochrome P450 (CYP450)-
mediated drug metabolism in mediating simvastatin-induced
responses, effects of CYP450 3A4 inhibitor was examined. The
biochemical existence of CYP450 3A4 protein was confirmed in
porcine coronary artery and human internal mammary artery
(Figure 9A). Porcine liver served as the positive control.
Ketoconazole (10 mM, a selective CYP450 3A4 inhibitor) failed
to modify simvastatin (10 mM)-induced changes of AMPK and
PP2A activities (Figure 9B and C).
Discussion
In this study, acute simvastatin (membrane permeable)
suppressed cromakalim- and pinacidil-induced relaxation of
U46619 pre-constricted (endothelium-denuded) arteries with no
effects on basal tension. In single myocytes of porcine coronary
artery and human left internal mammary artery, simvastatin and
AICAR inhibited cromakalim- and pinacidil-evoked KATP chan-
nel openings with no apparent effect on basal KATP channel
gatings. Thus, a prerequisite opening of KATP channels (by two
structurally different KATP channel openers cromakalim and
Figure 5. Effects of simvastatin on PP2A activation in porcine coronary artery. (A) Effects of simvastatin (10 mM) on the protein expression
of p-PP2A/total PP2A in porcine coronary artery. *P,0.05 and **P,0.01 compared to controls (i.e. time 0). (B) Effects of AICAR (1 mM) on the protein
expression of p-PP2A/total PP2A in porcine coronary artery. *P,0.05 and **P,0.01 compared to controls (i.e. time 0). (C) Effect of okadaic acid (O.A.,
10 nM) on simvastatin- and AICAR-induced protein expression of p-PP2A/total PP2A in porcine coronary artery. *P,0.05 and **P,0.01 compared to
controls (i.e. time 0). (D) Effect of compound C (10 mM) on simvastatin- and AICAR protein expression of p-PP2A/total PP2A in porcine coronary artery.
*P,0.05 and **P,0.01 compared to controls (i.e. time 0).
doi:10.1371/journal.pone.0066404.g005
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pinacidil) is necessary for simvastatin and AICAR to demonstrate
KATP channel blocking properties. However, simvastatin Na
+
(membrane impermeable) did not alter the cromakalim2/
pinacidil-induced relaxation and the KATP channel openings.
Therefore, these results suggest that the lipophilic property of
simvastatin is essential [3,34].
Acute application of HMG-CoA reductase inhibitors (prava-
statin, atorvastatin and cerivastatin) elicited an endothelium-
dependent relaxation of pre-constricted rat isolated aorta, and
cerivastatin-induced relaxation was attenuated by glibenclamide
and ouabain [13]. Activation of cardiac KATP channels by statins
has been reported [14,35,36]. However, a recent study [37] and
our current study demonstrated that simvastatin inhibits pinacidil-
induced relaxation in porcine isolated coronary artery. Further-
more, our result illustrate that simvastatin consistently suppressed,
instead of enhanced, cromakalim- and pinacidil-induced KATP
channel openings of arterial myocytes of pig coronary artery and
human left internal mammary artery. Taken together, these results
clearly illustrate that simvastatin could alter vasodilatation via the
inhibition of KATP channels.
AMPK (formerly termed HMG-CoA reductase kinase) is
activated by an increase in [AMP/ATP]i ratio and a rise in
[Ca2+]i which signals an increase in energy demands [38,39].
Once activated, AMPK decreases ATP consumption and/or
stimulates ATP production (e.g. via oxidative phosphorylation)
and the [ATP]i level is thus restored [40]. In human umbilical vein
endothelial cells (HUVECs), atorvastatin activated AMPK [25]
whereas in mouse pancreatic islets b-cells, AICAR (an AMPK
activator) inhibited KATP openings [41]. Acute application of
simvastatin significantly suppressed vasoconstriction of rat mesen-
teric resistance arteries via an AMPKa-phosphorylation-depen-
dent mechanism [42]. In addition, AICAR activates AMPK via an
increased phosphorylation, and phosphorylation (i.e. inactivation)
of a known target for AMPK i.e. HMG-CoA reductase occurred
[18,43,44]. However, in our study neither simvastatin nor
simvastatin Na+ (incubation # 30 min) altered the expression of
HMG-CoA reductase and p-HMG-CoA reductase-Ser871 (the
inactivated isoform of HMG-CoA reductase) suggesting that
AICAR and simvastatin are acting through different cellular
mechanisms (see below). In rat’s liver, AMPK is associated with
HMG-CoA reductase [45]. In our study, simvastatin and AICAR
Figure 6. Role(s) of [Ca2+]o and [Ca
2+]i in mediating the effects of simvastatin on AMPK and PP2A activities. (A) Effects of simvastatin
(10 mM), with and without ryanodine (100 mM) pre-treatment, on [Ca2+]i changes (F1/F0) of porcine coronary artery myocytes, estimated using Fluo-4/
AM with confocal laser scanning microscope. (B) Summary of [Ca2+]i changes in response to simvastatin (10 mM) before and after ryanodine (100 mM)
challenges. Results are expressed (Area Under Curve, AUC) as mean 6 SEM of 13–15 cells (***P,0.001). (C) Summary of the effects of ryanodine
(100 mM) on simvastatin (10 mM)- or AICAR (1 mM)-induced protein expression of p-AMPK/total AMPK in porcine coronary artery. *P,0.05 and
**P,0.01 compared to controls (i.e. time 0). (D) Summary of the effects of caffeine (1 mM) on the protein expression of p-AMPK/total AMPK in
porcine coronary artery, with and without ryanodine (100 mM). *P,0.05 and **P,0.01 compared to controls (i.e. time 0). (E) Effect of ryanodine
(100 mM) on simvastatin (10 mM)-induced protein expression of p-PP2A/total PP2A in porcine coronary artery. *P,0.05 and **P,0.01 compared to
controls (i.e. time 0). (F) Summary of the effect of simvastatin (10 mM), AICAR (1 mM) and caffeine (1 mM) on the protein expression of p-PP2A/total
PP2A, with and without KN93 (10 mM) in porcine coronary artery. *P,0.05 and **P,0.01 compared to controls (i.e. time 0).
doi:10.1371/journal.pone.0066404.g006
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Figure 7. Effects of simvastatin and AICAR on [Glucose]o uptake and the role(s) of [glucose]o and [Na
+]o in mediating simvastatin
effects on AMPK and PP2A activities. (A) Effects of simvastatin (10 mM) and AICAR (1 mM) on [3H]-2-deoxy-glucose uptake, with and without
compound C (10 mM), of porcine coronary artery myocytes (n = 6 for each treatment). *P,0.05 and **P,0.01 compared to controls. Summary of the
effect of simvastatin and AICAR on the protein expression of p-PP2A/total PP2A in (B) [glucose]o-free, (C) [Na
+]o-free, (D) with phloridzin (1 mM) and
(E) with ouabain (10 mM) in porcine coronary artery. *P,0.05 and **P,0.01 compared to controls (i.e. time 0).
doi:10.1371/journal.pone.0066404.g007
Simvastatin Inhibits KATP Channels
PLOS ONE | www.plosone.org 11 June 2013 | Volume 8 | Issue 6 | e66404
consistently increased p-AMPKa-Thr172 expression (i.e. activa-
tion) [44], and suppressed cromakalim- and pinacidil-induced
KATP channel openings. Taken together, our results illustrate that
acute simvastatin inhibits vascular KATP channel openings
probably via AMPKa-Thr172 phosphorylation (i.e. activation).
Okadaic acid (a potent PP2A inhibitor), but not rotterlin (a
PKC-d inhibitor) or H89 (a PKA inhibitor), reversed the inhibitory
effects of simvastatin on cromakalim- and pinacidil-mediated
KATP channel openings strengthen our conclusion on the
participation of PP2A. In contrast to cultured bovine aortic
endothelial cells (BAECs) [46], simvastatin- and AICAR-mediated
increase in PP2A-Tyr307 phosphorylation was abolished by
Compound C (an AMPK inhibitor) illustrating that PP2A is
phosphorylated (i.e. inactivated) in an ‘‘AMPKa-dependent’’
manner, and PP2A phosphorylation occurs at a site downstream
of AMPKa activation/phosphorylation. In addition, AMPK can
Figure 8. Effects of simvastatin on [ATP]i levels and LKB1 activation. (A) Summary of the effects of simvastatin (10 mM) and AICAR (1 mM) on
[ATP]i level with and without compound C (10 mM) of porcine coronary artery myocytes (n = 6 for each treatment). *P,0.05 and **P,0.01 compared
to controls. (B) Effect of AICAR (1 mM, n = 4) on the protein expression of p-LKB1/total LKB1 in porcine coronary artery. *P,0.05 and **P,0.01
compared to controls (i.e. time 0). (C) Effect of simvastatin (10 mM, n= 4) on the protein expression of p-LKB1/total LKB1 in porcine coronary artery.
*P,0.05 and **P,0.01 compared to controls (i.e. time 0).
doi:10.1371/journal.pone.0066404.g008
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be activated via the LKB1 (the upstream serine/threonine kinase
of AMPK) cascade [47]. In cultured BAECs, simvastatin (10 mM)
increased AMPKa-Thr172 phosphorylation via LKB1-Ser428
phosphorylation [5,8]. However, in our study, simvastatin (unlike
AICAR) did not cause LKB1-Ser428 phosphorylation of porcine
coronary artery suggesting that simvastatin-induced AMPKa-
Thr172 phosphorylation is mediated via a LKB1-Ser428 phosphor-
ylation-independent pathway.
Apart from LKB1, AMPK is activated/phosphorylated by
Ca2+/calmodulin-dependent kinase kinase (CaMKK) [48]. In our
study, caffeine- and simvastatin-induced AMPKa-Thr172 phos-
phorylation was abolished by KN93 (a selective Ca2+/calmodulin-
dependent protein kinase II (CaMK II) inhibitor) illustrating the
participation of Ca2+/CaMK II. In contrast, AICAR-induced
AMPKa-Thr172 phosphorylation was not affected by KN93
suggesting that AICAR-mediated AMPKa-Thr172 phosphoryla-
tion is CaMK II-independent [48]. In fact, our results illustrate
that AICAR increased p-LKB1-Ser428 expression suggesting that
AICAR phosphorylates AMPKa-Thr172 via the LKB1 pathway
[49].
Figure 9. Participation of cytochrome P450 3A4. (A) Biochemical existence of cytochrome 450 (CYP450 3A4) in porcine liver, porcine coronary
artery (endothelium denuded) and human left internal mammary artery (endothelium denuded). Beta actin was used as loading control. (B) Effects of
simvastatin on the protein expression of p-AMPK/total AMPK, with ketoconazole (Keto, 10 mM, n= 4), in porcine coronary artery (endothelium
denuded). *P,0.05 and **P,0.01 compared to controls (i.e. time 0). (C) Effects of simvastatin on the protein expression of p-PP2A/total PP2A, with
ketoconazole (Keto, 10 mM, n= 4), in porcine coronary artery (endothelium denuded). *P,0.05 and **P,0.01 compared to controls (i.e. time 0).
doi:10.1371/journal.pone.0066404.g009
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Figure 10. Proposed mechanisms for acute simvastatin-induced closure of KATP channels of vascular myocytes. Simvastatin (lipophilic)
crosses the plasma membrane and reaches the sacroplasmic reticulum (SR) of vascular myocytes. Binding of simvastatin to SR leads to the release of
ryanodine (Ryr)-sensitive Ca2+ into the cytosol. Elevation of Ca2+ activates CaMK II which leads to the subsequent activation (phosphorylation) of
AMPKa. Phosphorylation of AMPKa-Thr172 causes [glucose]o uptake with the participation of SGLT1 and Na
+/K+ ATPase. Increase in cytosolic [glucose]
leads to an elevation of ATP levels via oxidative phosphorylation. Elevation of [ATP]i serves two purposes: (1) closure of vascular KATP channels, (2)
providing phosphate groups for cellular proteins (e.g. PP2A and AMPK) phosphorylation. Phosphorylation of PP2A occurs downstream of AMPK
phosphorylation. PP2A phosphorylation results in PP2A inactivation which ‘‘releases’’ AMPK and thus phosphorylation of AMPKa-Thr172 resulted.
AICAR produces similar effects as simvastatin except the initial step involves LKB1-Ser428 phosphorylation.
doi:10.1371/journal.pone.0066404.g010
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Simvastatin inhibited Ca2+ release from intracellular stores of
smooth muscle cells [50,51]. As mentioned above, caffeine- and
simvastatin-induced AMPKa-Thr172 phosphorylation involved
CaMK II activation which is a Ca2+-dependent process. Similar
to rat aorta [52] and cultured BAECs [53], in our study
simvastatin caused a ryanodine-sensitive [Ca2+]i increase in
porcine coronary artery myocytes. Apart from Ca2+ release from
intracellular stores, the [Ca2+]i level is also modified by [Ca
2+]o
influx [54]. However, our results reveal that [Ca2+]o-free
conditions did not modify simvastatin-induced p-AMPKa-Thr172
expression. Neither nifedipine (a L-type Ca2+ channel blocker) nor
KB R-7953 (a reverse-mode Na+/Ca2+ exchanger blocker) altered
simvastatin-induced AMPKa-Thr172 phosphorylation. Taken to-
gether, the increased p-AMPKa-Thr172 expression is solely
dependent on ryanodine-sensitive [Ca2+]i release which is prob-
ably related to the distinct physiological location of HMG-CoA
reductase (i.e. sarco/endoplasmic reticulum) [1].
Activation of AMPK causes [glucose]o uptake [55], and in yeast
AMPK activation is regulated by PP2A in a [glucose]o-dependent
manner [56]. Although simvastatin and AICAR caused a
Compound C-sensitive increase in [3H]-2-deoxy-glucose uptake
into the myocytes, simvastatin- and AICAR-induced p-AMPKa-
Thr172 expression was [glucose]o2/[Na
+]o-independent. Hence,
ryanodine-sensitive Ca2+ release and activation of CaMK II, but
not [glucose]o uptake, are essential initial steps necessary for
AMPKa-Thr172 phosphorylation upon simvastatin challenge.
Nonetheless, our results demonstrate that simvastatin and AICAR
caused an increase in [ATP]i levels. The elevated [ATP]i
contributed to the closure of vascular KATP channels [57] as well
as providing phosphate groups necessary for protein (e.g. PP2A-
Tyr307) phosphorylation (see below).
AMPK is regulated negatively by serine/threonine phosphatas-
e(s) e.g. PP2A [46], and in rat’s liver HMG-CoA reductase is
associated with PP2A [45]. Our results clearly illustrate that
simvastatin-induced PP2A-Tyr307 phosphorylation (i.e. inactiva-
tion) [58] requires [glucose]o. In addition, Na
+/K+-ATPase
provides the favorable trans-cellular Na+ gradient for [glucose]o
uptake via Na+-glucose co-transporter (SGLT-1) [59]. Phloridzin
(a SGLT-1 inhibitor), [Na+]o depletion or ouabain suppressed
PP2A-Tyr307, but not AMPKa-Thr172, phosphorylation illustrat-
ing the obligatory role of [glucose]o uptake via SGLT-1 [60] with
the participation of Na+/K+-ATPase for PP2A-Tyr307 phosphor-
ylation.
The biochemical existence of cytochrome P450 (CYP450) 3A4
was demonstrated in porcine coronary artery and human left
internal mammary artery, and the possible local enzymatic
conversion of simvastatin into simvastatin Na+ by CYP450 3A4
[61] was considered. However, ketoconazole (a selective CYP450
3A4 inhibitor) failed to modify simvastatin-induced increase in p-
AMPKa-Thr172 and p-PP2A-Tyr307 expression refuted the
possibility of local bio-transformation of simvastatin. Thus, our
results strengthen the conclusion on the involvement of simvas-
tatin, but not simvastatin Na+, in inhibiting vascular KATP channel
openings.
In conclusion, our results demonstrate that acute simvastatin
caused phosphorylation of PP2A-Tyr307 and AMPKa-Thr172, but
not HMG-CoA reductase-Ser871, of porcine coronary artery.
Ryanodine-sensitive Ca2+ stores, but not [Ca2+]o entry, play an
obligatory role in simvastatin-elicited [Ca2+]i increase and initiated
the activation of Ca2+/CaMK II cascade which are essential for
the subsequent AMPKa-Thr172 phosphorylation (activation).
Activation of AMPKa leads to [glucose]o uptake (and [ATP]i
elevation resulted) with the participation of SGLT-1 and Na+/K+
ATPase. An increase in [ATP]i levels not only closed the KATP
openers-induced channels openings but also provided the neces-
sary phosphate groups for protein phosphorylation. Phosphoryla-
tion (inactivation) of PP2A-Tyr307 probably occurs at a site
downstream of AMPKa-Thr172 phosphorylation (Figure 10).
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